BioNTech

What BioNTech does

BioNTech is a publicly traded (NASDAQ: BNTX) German biopharmaceutical company founded in 2008 and headquartered in Mainz, with US operations in Cambridge, MA. Its core platform is proprietary messenger RNA (mRNA) immunotherapy technology spanning three complementary oncology modalities: individualized and shared neoantigen mRNA cancer vaccines, next-generation immunomodulators (led by the PD-L1xVEGF-A bispecific antibody pumitamig/BNT327, in seven Phase 3 trials), and antibody-drug conjugates (including trastuzumab pamirtecan partnered with Duality Biologics). The company also developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine, through its flagship partnership with Pfizer, and maintains an infectious-disease pipeline targeting malaria, tuberculosis, and mpox.

BioNTech monetizes through a partnership-heavy business model: milestone and royalty payments from the BMS co-development and co-commercialization deal (up to $11.1 billion for pumitamig) and the Pfizer Comirnaty partnership; licensing arrangements with Genentech/Roche, OncoC4, MediLink, Genmab, Genevant, Crescendo, Regeneron, and Autolus; CEPI grant funding for African manufacturing; and planned direct commercialization via a dedicated oncology sales force in the US and Europe. The proprietary BioNTainer modular manufacturing system enables scalable mRNA production and is being deployed in Kigali (Rwanda) and Melbourne (Australia). Pricing for COVID-19 vaccine is governed by multi-year government procurement contracts.

As of Q1 2026, BioNTech reported €118.1 million in revenue and a €531.9 million net loss, with FY2025 revenue of approximately €2.9 billion, FY2026 guidance of €2.0–2.3 billion, and €16.8 billion in cash reserves. The company is undergoing significant restructuring: closure of manufacturing facilities in Idar-Oberstein, Marburg, Tübingen, and Singapore by end of 2027 affecting ~1,860 positions (~22% of workforce), transfer of Comirnaty production to Pfizer, a $1 billion share buyback authorization, and the announced end-of-2026 departure of co-founders Prof. Ugur Sahin (CEO) and Prof. Özlem Türeci (CMO) to establish a new mRNA-focused venture.

Name

BioNTech

Legal name

BioNTech SE

Website

https://biontech.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

BioNTech is a German biopharmaceutical firm developing mRNA immunotherapies for cancer and infectious diseases, including the Comirnaty COVID-19 vaccine with Pfizer. The company is pivoting from COVID-19 manufacturing to an oncology pipeline of bispecific antibodies, mRNA cancer vaccines, and antibody-drug conjugates.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• MRNA immunotherapy
• Cancer therapeutics
• Infectious disease vaccines
• Bispecific antibodies
• Antibody-drug conjugates

Headquarters

HQ city

Mainz

HQ country

Germany

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. COVID-19 Vaccine (Comirnaty): mRNA COVID-19 vaccine developed in partnership with Pfizer. Revenue has declined sharply from pandemic-era peaks as demand normalizes. Manufacturing operations being wound down with production transferred to Pfizer.
2. Oncology Pipeline Revenue: BioNTech is advancing multiple oncology candidates through clinical trials with Bristol Myers Squibb and others. Potential future revenue from PD-L1xVEGF-A bispecific antibody, mRNA cancer immunotherapies, and ADCs pending regulatory approval.
3. R&D Partnerships and Milestone Payments: Collaboration agreements generating milestone payments from partners including Bristol Myers Squibb ($11.1 billion partnership), Duality Biologics, and other co-development arrangements. Includes technology licensing and royalty arrangements.
4. Manufacturing Services: COVID-19 vaccine manufacturing for partner Pfizer and potential future mRNA vaccine production for infectious diseases. African manufacturing facility in Rwanda being developed with CEPI funding.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

BioNTech SE develops and manufactures mRNA-based immunotherapies and vaccines targeting cancer and infectious diseases. Its commercial offering centers on the COVID-19 vaccine Comirnaty (developed with Pfizer), while its oncology pipeline includes individualized mRNA cancer vaccines, the PD-L1xVEGF-A bispecific antibody pumitamig (BNT327), antibody-drug conjugates such as trastuzumab pamirtecan, and the anti-CTLA4 antibody gotistobart. The company also markets the BioNTainer modular mRNA manufacturing system for scalable vaccine production in regions such as Africa and Australia.

Differentiator

Problem solved

Functional benefit

Products and services

• COMIRNATY (BNT162b2) COVID-19 Vaccine mRNA COVID-19 vaccine co-developed and manufactured with Pfizer for global distribution. Marketed under the Comirnaty brand. Sold to governments and healthcare systems for population immunization programs.
• BNT327 / Pumitamig (PD-L1xVEGF-A Bispecific Antibody) Next-generation immunomodulator candidate binding PD-L1 and VEGF-A simultaneously to act on two validated immuno-oncology mechanisms in the tumor microenvironment. In-licensed to Bristol Myers Squibb for co-development and co-commercialization across multiple solid tumor types; targeted for non-small cell lung cancer, among other indications.
• Individualized mRNA Cancer Immunotherapy (BNT122 / autogene cernumeran) Patient-specific mRNA cancer vaccine targeting individual tumor neoantigens. Designed for adjuvant setting after surgery or chemotherapy to address residual tumor cells and prevent disease recurrence. Co-developed with Genentech (Roche).
• Trastuzumab Pamirtecan (BNT323 / DB-1303) HER2-targeted antibody-drug conjugate for HER2-expressing cancers. In-licensed from Duality Biologics for $170 million upfront plus up to $1.5 billion in milestones. Lead ADC candidate in BioNTech's oncology pipeline.
• Gotistobart (BNT316 / ONC-392) Next-generation anti-CTLA-4 monoclonal antibody candidate developed in collaboration with OncoC4 as monotherapy or in combination across various cancer indications, including ovarian cancer.
• BioNTainer Modular mRNA Manufacturing System Modular containerized manufacturing units for scalable mRNA vaccine and therapeutic production. Deployable globally to enable regional vaccine manufacturing, including in underserved regions such as Africa, in partnership with CEPI and African governments.

Quantifiable outcome

• Pumitamig achieved 72.7% objective response rate in squamous NSCLC at 1400mg dose with 100% disease control
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered flagship, core and minor.

• Bristol Myers SquibbflagshipStrategic or Co-development Partner · 1 May 2024Global strategic partnership for co-development and co-commercialization of PD-L1xVEGF-A bispecific antibody (pumitamig/BNT327) across numerous solid tumor types. Deal valued at up to $11.1 billion including $1.5 billion upfront and $9.6 billion in milestones. Seven Phase 3 trials ongoing including head-to-head against pembrolizumab.
• Genentech (Roche Group)coreStrategic or Co-development PartnerPioneering collaboration to jointly research, develop, manufacture and commercialize individualized mRNA cancer immunotherapy targeting cancer neoantigens specific to individual patients. Six-year follow-up data showed 87.5% survival rate in pancreatic cancer patients with strong T cell responses.
• PfizerflagshipStrategic or Co-development PartnerGlobal partnership for COVID-19 vaccine Comirnaty development and distribution. Pfizer handles manufacturing and global distribution. BioNTech transferring COVID-19 vaccine production responsibility to Pfizer by end of 2026. Ongoing patent litigation between parties.
• Duality BiologicscoreStrategic or Co-development PartnerGlobal strategic partnership to accelerate ADC research and development. BioNTech acquired rights from DualityBio in April 2023 for $170 million upfront plus up to $1.5 billion milestones. Lead candidate trastuzumab pamirtecan showed 47.9% response rate in HER2-expressing endometrial cancer.
• OncoC4coreStrategic or Co-development PartnerCollaboration for research and development of next-generation anti-CTLA4 monoclonal antibody candidate (gotistobart) as monotherapy or combination therapy in various cancer indications. Phase 3 data showed 54% reduction in death risk in ovarian cancer.
• MediLink TherapeuticsminorStrategic or Co-development PartnerGlobal strategic partnership to develop multiple next-generation antibody-drug conjugate candidates.
• Crescendo BiologicsminorStrategic or Co-development PartnerMulti-target discovery collaboration to develop novel immunotherapies for cancer treatment using Crescendo's proprietary platform for precision immunotherapies including mRNA-based antibodies.
• GenmabcoreStrategic or Co-development PartnerLicense and collaboration agreement to develop tumor-targeted and dual immunomodulator antibodies using Genmab's proprietary technologies combined with BioNTech's target identification expertise.
• Genevant SciencescoreTechnology or IntegrationStrategic collaboration for mRNA-based protein replacement therapies with exclusive licenses to Genevant's lipid nanoparticle (LNP) drug delivery technology for specified oncology targets.
• Autolus TherapeuticsminorStrategic or Co-development PartnerCollaboration to advance both companies' autologous CAR-T programs. BioNTech supports launch and expansion of Autolus' lead cell therapy product in exchange for royalty payments.
• RegeneroncoreStrategic or Co-development PartnerStrategic collaboration in oncology for development of novel cancer immunotherapies.
• Kite Pharma (Gilead)coreTechnology or IntegrationBioNTech acquired Kite's solid tumor neoantigen TCR R&D platform and manufacturing facility in Gaithersburg, MD in July 2021 to enhance cell therapy pipeline and expand manufacturing capabilities in North America.
• Boehringer IngelheimminorStrategic or Co-development PartnerPhase Ib/II clinical trial collaboration evaluating Boehringer's DLL3-targeting T-cell engager obrixtamig combined with BioNTech's pumitamig in extensive-stage small cell lung cancer.
• CureVaccoreTechnology or IntegrationBioNTech acquired CureVac in 2024 for €1.25 billion, gaining access to CureVac's next-generation mRNA technology and manufacturing capabilities. CureVac subsequently filed patent infringement lawsuit against Moderna.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Moderna: Direct mRNA platform competitor with COVID-19 vaccine (Spikevax) and growing oncology pipeline. Most comparable peer given shared mRNA technology foundation, similar pivot from infectious disease to oncology, and direct involvement in patent litigation with BioNTech (via CureVac).
• Bristol Myers Squibb: BMS is both co-development partner for pumitamig and a competitor with its own PD-(L)1 inhibitor (Opdivo/nivolumab) and bispecific franchises. The head-to-head pumitamig vs pembrolizumab trial directly pits BioNTech against Merck, but BMS's IO commercial strategy shapes pricing and access dynamics across the same indications.
• Regeneron: Strategic partner on BioNTech's oncology programs and a direct competitor in bispecific antibodies (e.g., linvoseltamab, odronextamab) and ADCs. Regeneron's growing oncology footprint and combination trial activity make it a closely comparable mid-to-late-stage clinical peer.
• Gilead Sciences / Kite Pharma: BioNTech acquired Kite's solid tumor neoantigen TCR platform in 2021. Gilead/Kite is both a former seller and an indirect competitor in cell therapy and immuno-oncology, particularly as BioNTech expands its autologous and allogeneic cell therapy programs.
• Sanofi: Sanofi has invested in BioNTech (2019) and runs competing mRNA and oncology programs through its vaccines and specialty care divisions. Comparable as an investor/partner with overlapping R&D scope in vaccines and immuno-oncology.

Broad incumbents

• Merck & Co. Keytruda (pembrolizumab) is the anti-PD-1 benchmark against which pumitamig is being tested head-to-head. Merck is the dominant IO incumbent whose revenue BioNTech's lead asset directly targets, and Merck's combination strategies shape the competitive landscape for the entire oncology pipeline.
• Roche / Genentech: Strategic partner on individualized mRNA cancer vaccines and a broad oncology incumbent with TECENTRIQ, HER2 franchises, and a deep bispecific pipeline. Comparable as both an enabler of BioNTech's neoantigen program and a competitor in overlapping HER2/ADC and IO indications.
• AstraZeneca: Established oncology incumbent with IMFINZI (durvalumab), Enhertu (HER2 ADC via partnership with Daiichi Sankyo), and a broad bispecific pipeline. Directly relevant comparand for pumitamig's competitive positioning across NSCLC, endometrial, and other solid tumor indications.
• Pfizer: Long-term Comirnaty partner that is taking over COVID-19 manufacturing. Pfizer's broader oncology portfolio (including Seagen ADCs) makes it both an enabler of BioNTech's infectious disease franchise and a competitor in HER2 ADCs (e.g., trastuzumab pamirtecan's competitive set).

Emerging players

• CureVac: Acquired by BioNTech in 2025 for €1.25B. Historically a direct mRNA vaccine peer; now integrated as a wholly-owned subsidiary contributing mRNA stabilization IP and ongoing patent litigation against Moderna that may reshape industry-wide licensing economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/BioNTech_Group
• YouTubeyoutube.com/@biontech2008
• LinkedInlinkedin.com/company/biontech-se

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries3 records

Funding overview

Funding rounds13 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioNTech